This is obviously a tough question that patients and docs need to consider on a case-by-case basis. If I were a null responder, I'd try to enroll to a clinical trial including at least two DAA agents plus SOC. If that's not possible and I have an advanced histologic disease, I might consider T+SOC.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.